Oric PharmaceuticalsORIC
ORIC
About: ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
Employees: 122
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
6,175% more call options, than puts
Call options by funds: $3.26M | Put options by funds: $52K
96% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 26
35% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 20
25% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 5 (+1) [Q4]
8.42% more ownership
Funds ownership: 98.98% [Q3] → 107.4% (+8.42%) [Q4]
6% more funds holding
Funds holding: 122 [Q3] → 129 (+7) [Q4]
14% less capital invested
Capital invested by funds: $715M [Q3] → $612M (-$103M) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$12
146%
upside
Avg. target
$18.67
283%
upside
High target
$22
352%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Robert Burns 24% 1-year accuracy 39 / 165 met price target | 352%upside $22 | Buy Maintained | 9 May 2025 |
Oppenheimer Matthew Biegler 12% 1-year accuracy 3 / 26 met price target | 146%upside $12 | Outperform Maintained | 6 May 2025 |
JP Morgan Anupam Rama 21% 1-year accuracy 12 / 57 met price target | 352%upside $22 | Overweight Maintained | 26 Feb 2025 |
Financial journalist opinion
Based on 4 articles about ORIC published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates
Announced focused registrational clinical development plans for lead programs, extended cash runway, and accelerated/augmented corporate milestones
Neutral
GlobeNewsWire
1 week ago
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO Calif. and SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on May 1, 2025 (the “Grant Date”), ORIC granted a total of 32,400 non-qualified stock options and 5,200 restricted stock units to four new non-executive employees who began their employment with ORIC in April 2025.
Neutral
GlobeNewsWire
2 weeks ago
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the presentation of a poster at the 2025 American Association for Cancer Research (AACR) Annual Meeting, highlighting preclinical data on ORIC-944, a potent, highly selective, orally bioavailable allosteric inhibitor of PRC2, which demonstrated synergistic activity and improved progression-free survival (PFS) when combined with androgen receptor pathway inhibitors (ARPIs) in models of prostate cancer.
Neutral
Seeking Alpha
3 weeks ago
ORIC Pharmaceuticals: Multiple Data Releases In 2025 Make It A Must-Watch Biotech
ORIC Pharmaceuticals is advancing ORIC-114 for 1st-line EGFR/HER2 exon 20 NSCLC, with comprehensive data expected in the 2nd half of 2025 and a phase 3 trial to start in 2026. ORIC-944 in combination with ERLEADA and/or NUBEQ is being tested for the treatment of patients with metastatic castration-resistant prostate cancer; Data readouts from dose-optimization cohorts expected in 2025. The global prostate cancer market is expected to reach $29.2 billion by 2035; Approximately between 10% to 20% of all prostate cancers are as classified as castration-resistant.
Neutral
GlobeNewsWire
1 month ago
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on April 1, 2025 (the “Grant Date”), ORIC granted a total of 50,600 non-qualified stock options and 8,250 restricted stock units to three new non-executive employees who began their employment with ORIC in March 2025.
Neutral
GlobeNewsWire
1 month ago
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in April:
Neutral
GlobeNewsWire
1 month ago
ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that a preclinical abstract highlighting the potential of ORIC-944, a potent and selective allosteric inhibitor of PRC2 to treat prostate cancer, has been accepted for poster presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting taking place April 25-30, 2025 in Chicago, IL.
Neutral
GlobeNewsWire
2 months ago
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on March 3, 2025 (the “Grant Date”), ORIC granted a total of 26,450 non-qualified stock options and 4,300 restricted stock units to three new non-executive employees who began their employment with ORIC in February 2025.
Neutral
GlobeNewsWire
2 months ago
ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones
Anticipated registrational development plans for ORIC-944 and ORIC-114 prioritized to focus on indications with strongest clinical validation and highest unmet need
Neutral
GlobeNewsWire
2 months ago
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates
Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor inhibitors in patients with mCRPC
Charts implemented using Lightweight Charts™